These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32150105)

  • 1. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: A retrospective analysis.
    Xia G; Jiang R
    Medicine (Baltimore); 2020 Mar; 99(10):e19466. PubMed ID: 32150105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel multivariate logistic model for predicting risk factors of failed treatment with carbapenem-resistant
    Sun K; Peng F; Xu K; Liu Y; Zhou X; Shang N; Li C
    Front Public Health; 2024; 12():1385118. PubMed ID: 38784576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases: A meta-analysis.
    Gong J; Su D; Shang J; Yu H; Du G; Lin Y; Sun Z; Liu G
    Medicine (Baltimore); 2019 Sep; 98(38):e17091. PubMed ID: 31567945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units.
    Bai XR; Wang ZZ; Li WC; Wang YG; Lou R; Qu X; Fan L; Zhang W; Wu YC; Yan SY; Zhang L
    BMC Infect Dis; 2023 Nov; 23(1):830. PubMed ID: 38012576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.
    Jung SY; Lee SH; Lee SY; Yang S; Noh H; Chung EK; Lee JI
    Crit Care; 2017 Dec; 21(1):319. PubMed ID: 29262831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of multidrug-resistant bacteria and clinical outcomes in patients with infected diabetic foot in a Peruvian hospital: A retrospective cohort analysis.
    Yovera-Aldana M; Sifuentes-Hermenegildo P; Cervera-Ocaña MS; Mezones-Holguin E
    PLoS One; 2024; 19(6):e0299416. PubMed ID: 38833431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute liver failure caused by high-dose tigecycline: A case report.
    Zhang Y; Wang J; Tan Y; Wu J
    Int J Clin Pharmacol Ther; 2024 Jul; 62(7):339-344. PubMed ID: 38606856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review on Analytical Methods for Tigecycline Estimation From Its Bulk and Dosage Form.
    Rakholiya B; Shah P; Patel Y; Patel G; Patel S; Patel A
    J AOAC Int; 2023 Nov; 106(6):1689-1695. PubMed ID: 37676830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and Validation of Models for the Risk of Multi-Drug Resistant Bacteria Infection and Prognosis in Elderly Patients with Pulmonary Infection: A Multicenter Retrospective Study.
    Wang S; Li J; Dai J; Zhang X; Tang W; Li J; Liu Y; Wu X; Fan X
    Infect Drug Resist; 2023; 16():6549-6566. PubMed ID: 37817839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections.
    De Pascale G; Lisi L; Ciotti GMP; Vallecoccia MS; Cutuli SL; Cascarano L; Gelormini C; Bello G; Montini L; Carelli S; Di Gravio V; Tumbarello M; Sanguinetti M; Navarra P; Antonelli M
    Ann Intensive Care; 2020 Jul; 10(1):94. PubMed ID: 32661791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Dose Tigecycline in Elderly Patients with Pneumonia Due to Multidrug-Resistant
    Bai XR; Jiang DC; Yan SY
    Infect Drug Resist; 2020; 13():1447-1454. PubMed ID: 32547113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High doses of tigecycline are associated with satisfactory plasmatic and pulmonary concentrations for the treatment of severe infections due to fully susceptible bacteria: do we need even higher doses in patients under CRRT?
    Honore PM; Barreto Gutierrez L; Kugener L; Redant S; Attou R; Gallerani A; De Bels D
    Ann Intensive Care; 2020 Oct; 10(1):139. PubMed ID: 33052490
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of Tigecycline's MIC in the Outcome of Critically Ill Patients with Carbapenemase-Producing
    Papadimitriou-Olivgeris M; Bartzavali C; Nikolopoulou A; Kolonitsiou F; Mplani V; Spiliopoulou I; Christofidou M; Fligou F; Marangos M
    Antibiotics (Basel); 2020 Nov; 9(11):. PubMed ID: 33228012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.
    Bhowmick T; Weinstein MP
    Infect Dis Ther; 2020 Dec; 9(4):757-767. PubMed ID: 33017041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis.
    Li YY; Wang J; Wang R; Cai Y
    BMC Infect Dis; 2020 Jun; 20(1):408. PubMed ID: 32527246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review.
    Liu YX; Le KJ; Shi HY; Zhang ZL; Cui M; Zhong H; Yu YT; Gu ZC
    Transl Androl Urol; 2021 Jan; 10(1):292-299. PubMed ID: 33532318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Prospective and Retrospective Methods of a Tigecycline Post-Marketing Surveillance Study in the Safety Outcomes of Patients with Complicated Skin Structure Infection, Complicated Intraabdominal Infection and Community-Acquired Pneumonia.
    Chi W; Lee HJ; Chong YP
    Infect Dis Ther; 2021 Mar; 10(1):411-420. PubMed ID: 33483853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.
    Yaghoubi S; Zekiy AO; Krutova M; Gholami M; Kouhsari E; Sholeh M; Ghafouri Z; Maleki F
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1003-1022. PubMed ID: 33403565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia.
    Zhou Y; Xu P; Li H; Wang F; Yan H; Liang W; Xiang D; Zhang B; Banh HL
    Br J Clin Pharmacol; 2021 Jul; 87(7):2838-2846. PubMed ID: 33283892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature.
    Fan Q; Huang W; Weng Y; Xie X; Shi Z
    Medicine (Baltimore); 2020 Oct; 99(43):e22638. PubMed ID: 33120753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.